Vlado Perkovic's Publications

• Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy

  Journal articles

  2024

  Kidney International Reports

• Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

  Journal articles

  2024

  Nature Medicine

• Kidney Disease as a Cardiovascular Disease Priority

  Journal articles

  2024

  Circulation

• Risk of Relapse of Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids

  Journal articles

  2024

  Arthritis and Rheumatology

• Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  European Journal of Heart Failure

• Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism

• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD A Meta-Analysis of CKD Progression Trials

  Journal articles

  2024

  Clinical Journal of the American Society of Nephrology

• Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

  Journal articles

  2024

  EUROPEAN HEART JOURNAL

• Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

  Journal articles

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

  Journal articles

  2024

  The Lancet Diabetes and Endocrinology

• Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism

• Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials

  Journal articles

  2024

  Circulation

• Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes

  Journal articles

  2024

  New England Journal of Medicine

• The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy

  Journal articles

  2024

  Kidney International Reports

• Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

  Journal articles

  2024

  Circulation

• Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study

  Conference Abstracts

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IGAN STUDY

  Conference Abstracts

  2024

  AMERICAN JOURNAL OF KIDNEY DISEASES

• Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study

  Conference Abstracts

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• SPARSENTAN (SPAR) SHOWS CLINICALLY MEANINGFUL TREATMENT EFFECTS VS IRBESARTAN (IRB) IN PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE PHASE 3 PROTECT TRIAL

  Conference Abstracts

  2024

  AMERICAN JOURNAL OF KIDNEY DISEASES

• Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)

  Journal articles

  2024

  American Journal of Respiratory and Critical Care Medicine

• Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Daprodustat and Heart Failure in CKD

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

  Journal articles

  2024

  Kidney International Reports

• The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

  Journal articles

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

  Journal articles

  2024

  Diabetes Care

• VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

  Journal articles

  2024

  Journal of the American Society of Nephrology